Italian Medicines Agency Agenzia Italiana del Farmaco

AIFA authorises the therapeutic use of the monoclonal Evusheld for the early treatment of COVID-19 in subjects at risk of progression - AIFA authorises the therapeutic use of the monoclonal Evusheld for the early treatment of COVID-19 in subjects at risk of progression

Asset Publisher

AIFA authorises the therapeutic use of the monoclonal Evusheld for the early treatment of COVID-19 in subjects at risk of progression

Press release n. 695 - AIFA's Scientific Technical Committee (STC) has authorised the use of the monoclonal antibody Evusheld (tixagevimab and cilgavimab) in the early treatment of SARS-CoV-2 infected subjects at risk of a severe form of COVID-19.

Until now, the medicine was only available for pre-exposure prophylaxis in high-risk subjects. With this extension of indication, AIFA makes available an intramuscular therapeutic option for subjects in whom the prescription of antiviral medicines and authorised monoclonal antibodies is considered inappropriate from a clinical and/or epidemiological point of view (in relation to the circulation of viral variants).
The AIFA's decision to authorise Evusheld for the treatment of patients with COVID-19 anticipates the EMA's assessment, which will be completed in September 2022, and is based on both the results of already published clinical trials and the interim analysis (on approximately 450 patients) of a multicentre study currently underway in Italy (Mantico-2, coordinated by prof.ssa Tacconelli, University of Verona), funded by the Agency with the aim of comparing three different alternatives (Evusheld, Paxlovid and Xevudy) in the early treatment of patients with COVID-19.

Evusheld was therefore included in the list of drugs that can be dispensed by the National Health Service under Law 648/96. For prescribing procedures, please refer to AIFA's institutional website.

The resolution is published today in the Official Journal and will take effect tomorrow, 3 August 2022.


Published on: 02 August 2022

Asset Publisher

Asset Publisher

Galleria

Nested Applications

Last tweets

👵🏻👴🏻 Oggi è la Festa dei Nonni: un giorno per ringraziarli e per pensare alla loro salute. Con l...
Vai al post →
🤝 A Lisbona l’incontro istituzionale tra #AIFA e l’Autorità Nazionale del Farmaco portoghese. 📚 L...
Vai al post →
Davanti a un barattolo di caramelle scegliamo il gusto che ci ispira di più. Fragola, menta, liquiri...
Vai al post →
💜 World Alzheimer's Day - #21settembre AIFA si tinge di viola per celebrare la Giornata Mondiale de...
Vai al post →
💊 Paracetamolo per il mal di testa, spray per il naso chiuso: i #farmaci da banco rendono facile tr...
Vai al post →
💊 Carenze di #farmaci in UE 🤝#AIFA ospita study visit con rappresentanti di 9 Agenzie regolatorie ...
Vai al post →

Go to Twitter profile

Multimedia

Cookie Bar

cookie management module

Descrizione cookieBar

Questo sito utilizza cookie tecnici e analytics, necessari al suo funzionamento, per i quali non è richiesto il consenso. Per alcuni servizi aggiuntivi, le terze parti fornitrici, dettagliatamente sotto individuate, possono utilizzare cookies tecnici, analytics e di profilazione. Per saperne di più consulta la PRIVACY POLICY. Per proseguire nella navigazione devi effettuare la scelta sui cookie di terze parti dei quali eventualmente accetti l’utilizzo. Chiudendo il banner attraverso la X in alto a destra rifiuti tutti i cookie di terze parti. Puoi rivedere e modificare le tue scelte in qualsiasi momento attraverso il link "Gestione cookie" presente nel footer.

Social networks
go to beginning of content